Upcoming stock buybacks

Upcoming stock buybacks

Posted: givejob80 On: 03.06.2017

Healthcare continues to be one of the most volatile industries enteringmaking it a great time for diligent investors to capitalize on opportunities in the space. Check out our top picks for important data releases and healthcare catalysts to track in the first quarter.

After another roller-coaster year in the healthcare space, investors are trying to stay positive while repositioning for the Trump presidency. Throughout merger volume and valuations fell from the historically the high levels seen in and Although political rhetoric surrounding the Affordable Care Act is destined to bring more volatility inthere are many reasons to have a positive outlook on the sector.

upcoming stock buybacks

Demand for health services continues to increase as baby boomers age. Dominant players in the space have also started employing new strategies due to public and political pressure to lower drug prices. While regulatory concerns and fiscal policy changes could continue to bring volatility innow is a great time for diligent investors to capitalize on low valuations across the industry.

Here is a list of regulatory and data related events coming in the first quarter that healthcare investors should be watching closely. A Note to Our Readers: The links on each section subheading direct to Slingshot Investments' registration pages for further information. PDUFA Date of January 7th for Pfizer's Crisaborole in Atopic Dermatitis. S patients with atopic dermatitis. The transaction was carried out as a bolt-on acquisition through Pfizer's subsidiary Quattro Merger Sub Inc to increase the value of PFE.

The success of these transactions is very important in creating shareholder confidence in Pfizer's leadership. The topical drug has proven to be efficacious and well tolerated, and could fill the significant unmet need for a non-steroidal option in the market.

upcoming stock buybacks

Crisaborole is also being tested in psoriasis, and Pfizer is currently exploring regulatory filings outside of the U. If it is approved by the FDA this week, the drug will help Pfizer continue to grow in profitability and regain stability after a volatile year. Assuming it is approved, Slingshot Insights would like to conduct an expert interview in the coming weeks on the market potential of crisaborole. PDUFA date of January 29th for Synergy's Plecanatide.

Supplemental NDA filing also due in the first quarter.

The drug is a once-daily tablet being tested in chronic idiopathic constipation [CIC] and irritable bowel syndrome with constipation [IBS-C]. The upcoming PDUFA date is for CIC, but Synergy also has plans to submit an sNDA in IBS-C during this quarter. Plecanatide has shown promising results through clinical trials, and there are only two FDA approved treatment options for CIC and IBS-C Amitiza, Linzess.

An estimated 45 million adults suffer from CIC or IBS-C in the U. If the product is approved it could capitalize on this significant unmet need in the market, and be a major value driver for Synergy. We conducted an interview with a leading gastroenterologist on the Phase 3 data for Plecanatide versus Linzess-and interpreting CIC versus IBS-C data where he makes particularly useful comments about relative side effect rates vs.

Rigel's NDA filing for Fostamatinib in Immune Thrombocytopenic Purpura. It is being tested across three indications: Immune Thrombocytopenia [ITP], Autoimmune Hemolytic Anemia [AIHA], and IgA Nephropathy [IgAN]. Only 50, to 60, people suffer from the autoimmune disease, and the majority of patients are women. It is currently hard to predict what treatments work for patients, and there is no one drug that works for everyone.

Approval of fostamatinib would give healthcare professionals a new product to try for difficult-to-treat patients, and be a significant step towards profitability for Rigel. Recent data presents a serious obstacle towards achieving this, and investors should watch closely the month following submission to see if the FDA accepts the application for review. On our expert call with a leading hematologist from Mount Sinai, the expert discussed the Phase 3 expectations and chances of approval.

Aerie NDA Refiling Expected Towards End of Q1 for Rhopressa in Glaucoma.

SunTrust Robinson Humphrey Biotech Stock Picks With Big Upcoming Catalysts - 24/7 Wall St.

Another regulatory event to keep an eye on this quarter is a NDA resubmission for Aerie's NASDAQ: AERI Rhopressa in elevated intraocular pressure [IOP] in glaucoma patients. Aerie withdrew the NDA in October because the third party manufacturer was not ready for pre-approval inspection by the Upcoming stock buybacks.

They recently announced that the facility will not be ready for inspection until the end of February, and that NDA filing will be delayed until the end of Q1.

While this is obviously a major concern for any Aerie investor, the drug could become the first approved once-daily product to target the trabecular meshwork responsible for high IOP.

Company Stock Buybacks: Good or Bad?

Before the original NDA submission Slingshot Insights conducted an interview discussing Aerie's glaucoma program with a leading ophthalmologist from the University of Illinois. Neurocrine Top-line Phase 2 Data Evaluating Ingrezza in Adults and Pediatrics with Tourette Syndrome due early Ingrezza, one of Neurocrine's NASDAQ: NBIX lead product candidates, will have its fate revealed in the coming months.

Phase 2 data from T-Forward evaluating adults with Tourette Syndrome and T-Force evaluating pediatrics will be released soon. The results will help management and the FDA Advisory Committee decide if a Phase 3 trial is necessary before submitting an NDA in Tourette Syndrome.

Ingrezza already has a PDUFA date of April 11th for Tardive Dyskinesia, which will also give investors insight into how the FDA views the drug. Slingshot Insights is planning to conduct an expert interview in the benelli sbe ii/m2/ non-comfortech synthetic stock two weeks to discuss the coming data release, upcoming stock buybacks what it means for the drug's chances of success.

Cidara Phase 2 RADIANT Data Release for Topical CD in Yeast Infection. CDTX is another micro-cap due to release data on their lead candidate in the first quarter.

CD is a echinocandin antifungal, the first and only agent in royal dutch shell b share price today class being evaluated for the treatment and prevention of yeast infections. The company is also developing intravenous CD for candidemia and invasive yeast infections; and an immunotherapy discovery platform called Cloudbreak that gives the stock significant potential upside.

Trevena Phase 3 APOLLO 1 and APOLLO 2 data due Q1 for Oliceridine in Moderate to Severe Acute Pain. TRVN is a small-cap company trying to break into the crowded pain management market with their lead candidate Oliceridine.

The drug is an intravenous mu opioid receptor that Trevena believes could potentially replace IV opioid analgesics. It has demonstrated comparable pain relief, but most of its potential values lies in a minimal side effect profile relative to opioids. Top-line Phase 3 data is due this quarter from APOLLO 1 in patients following bunionectomy removal of a bunionand APOLLO 2 in patients following abdominoplasty tummy tuck.

NDA submission is planned for the second half ofand positive data from APOLLO will undoubtedly improve Trevena's chances of breaking into the market. The only nano-cap on this list, Ritter NASDAQ: The company is focused on the development of novel therapeutics to treat gastrointestinal diseases, and RP-G28 has the potential to be the first approved product for lactose intolerance.

S on over-the-counter lactose intolerance aids. Ritter also believes the compound may have applicability to Crohn's disease, tesla stock post market bowel syndrome, inflammatory bowel disease, and ulcerative colitis.

Ultragenyx Phase 2 Data Release for UX in Glut1 Deficiency Syndrome Patients. Although they have no approved products, Ultragenyx NASDAQ: RARE has numerous candidates for different rare diseases with UX as the lead drug in their pipeline. Positive week Phase 2 data in LC-FAOD was released in late November, and Slingshot Insights is planning to conduct an expert interview to analyze the data and the drug's potential for success in the market.

Progenics Phase 2b data due for Azedra in Pheochromocytoma in the First Quarter. Positive data this quarter will lead Progenics to file an NDA in the first half of the year, and the company believes the drug is well positioned for commercialization in late Whether that movement is up or down in the short term will likely depend on the success of Azedra, and shareholders should watch closely for the upcoming Phase 2b data.

Slingshot Insights conducted two expert interviews in September assessing the potential of Azedra compared to conventional I MIBG. Roche Phase 3 APHINITY Results Expected in Q1 Evaluating Perjeta in Adjuvant Treatment of HER2-Positive Breast Cancer.

RHHBY was originally supposed to release the data by the end ofinvestors are eagerly waiting for the Phase 3 data release for perjeta in HER2-positive breast cancer. The drug is already approved for combination use with herceptin and docetaxel, and is one of the faster growing in terms of sales for Roche. Data from Amgen's Phase 3 FOURIER Coronary Imaging Study Evaluating Repatha in High Cholesterol Patients Expected Q1 AMGN Repatha is an already approved injectable PCSK9 inhibitor used with statin therapy to lower levels of LDL cholesterol.

Amgen investors are waiting for important cardiovascular imaging results from their Phase 3 study that will show the effect of the drug on atherosclerotic plaque in the coronary arteries. This a major underlying cause of cardiovascular disease, and successful results will be a major step in establishing Repatha as an important therapy in this area. The product has yet to become a major source of sales for the company, but there is hope that positive results will lead to further adoption from cardiovascular specialists and general practitioners.

Slingshot Insights would like to conduct an interview with a cardiologist before the data release to get a better understanding of the potential of repatha.

upcoming stock buybacks

These are just some of the key catalysts that are coming up for the biotech sector in the first quarter of Slingshot Insights has an extensive, searchable database of all the key value driving events for the sector. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it.

I have no business relationship with any company whose stock is mentioned in this article.

Stocks Buffett Hinted Are Undervalued Based on Buybacks - bozunoteyuta.web.fc2.com

This article discusses one or more securities that do not trade on a major U. Please be aware of the risks associated with these stocks. Long Ideas Short Ideas Cramer's Picks IPOs Quick Picks Sectors Editor's Picks. What To Watch In Q1: Upcoming Healthcare Regulatory Events And Data Releases Jan. Summary Healthcare continues to be one of the most volatile industries enteringmaking it a great time for diligent investors to capitalize on opportunities in the space.

CSBK stock quote - Clifton Bancorp Inc. Common Stock price - bozunoteyuta.web.fc2.com

Stay up to date on important regulatory events coming in Q1. Phil Loria After another roller-coaster year in the healthcare space, investors are trying to stay positive while repositioning for the Trump presidency. PDUFA Date of January 7th for Pfizer's Crisaborole in Atopic Dermatitis Pfizer NYSE: Want to share your opinion on this article? Disagree with this article? To report a factual error in this article, click here. Follow Slingshot Insights and get email alerts.

inserted by FC2 system